CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
CERo Therapeutics Holdings (NASDAQ: CERO) has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. The compliance was achieved through multiple financial moves including a private placement of Series D Preferred Stock, a partial drawdown from the Company's Equity Line of Credit, and a public offering completed in February 2025.
The Nasdaq Hearings Panel confirmed the company's compliance on May 7, 2025. CEO Chris Ehrlich highlighted that the company can now focus on advancing its lead program, CER-1236, an immunotherapy treatment for cancer. CERo expects to initiate the first dose of its Phase 1 clinical trial soon and plans to provide regular updates on its progress.
CERo Therapeutics Holdings (NASDAQ: CERO) ha riconquistato con successo la conformità al requisito minimo di patrimonio netto di Nasdaq pari a 2,5 milioni di dollari. Tale conformità è stata raggiunta attraverso diverse operazioni finanziarie, tra cui un collocamento privato di Azioni Preferenziali Serie D, un prelievo parziale dalla linea di credito azionaria della società e un'offerta pubblica completata a febbraio 2025.
Il Nasdaq Hearings Panel ha confermato la conformità dell'azienda il 7 maggio 2025. L'amministratore delegato Chris Ehrlich ha sottolineato che ora l'azienda può concentrarsi sull'avanzamento del suo programma principale, CER-1236, un trattamento immunoterapico per il cancro. CERo prevede di somministrare presto la prima dose della sua sperimentazione clinica di Fase 1 e intende fornire aggiornamenti regolari sui progressi.
CERo Therapeutics Holdings (NASDAQ: CERO) ha recuperado con éxito el cumplimiento del requisito mínimo de patrimonio neto de Nasdaq de 2,5 millones de dólares. El cumplimiento se logró mediante varias operaciones financieras, incluyendo una colocación privada de acciones preferentes Serie D, un retiro parcial de la línea de crédito de capital de la compañía y una oferta pública completada en febrero de 2025.
El Panel de Audiencias de Nasdaq confirmó el cumplimiento de la empresa el 7 de mayo de 2025. El CEO Chris Ehrlich destacó que la compañía ahora puede centrarse en avanzar en su programa principal, CER-1236, un tratamiento inmunoterapéutico para el cáncer. CERo espera iniciar pronto la primera dosis de su ensayo clínico de Fase 1 y planea proporcionar actualizaciones regulares sobre su progreso.
CERo Therapeutics Holdings (NASDAQ: CERO)는 나스닥의 최소 주주 자본금 250만 달러 요건을 성공적으로 충족했습니다. 이 요건 충족은 시리즈 D 우선주 사모 발행, 회사의 자본 신용 한도 일부 인출, 2025년 2월 완료된 공개 모집 등 여러 재무 조치를 통해 이루어졌습니다.
나스닥 청문회 패널은 2025년 5월 7일 회사의 준수 여부를 확인했습니다. CEO 크리스 얼리히는 회사가 이제 암 면역치료제인 CER-1236 주력 프로그램 개발에 집중할 수 있게 되었다고 강조했습니다. CERo는 곧 1상 임상시험 첫 투약을 시작할 예정이며 진행 상황에 대해 정기적으로 업데이트할 계획입니다.
CERo Therapeutics Holdings (NASDAQ : CERO) a réussi à retrouver la conformité au seuil minimum de capitaux propres exigé par le Nasdaq, fixé à 2,5 millions de dollars. Cette conformité a été atteinte grâce à plusieurs opérations financières, notamment un placement privé d’actions privilégiées de série D, un tirage partiel sur la ligne de crédit en actions de la société, ainsi qu’une offre publique finalisée en février 2025.
Le panel d’audiences du Nasdaq a confirmé la conformité de l’entreprise le 7 mai 2025. Le PDG Chris Ehrlich a souligné que la société peut désormais se concentrer sur l’avancement de son programme principal, CER-1236, un traitement immunothérapeutique contre le cancer. CERo prévoit d’administrer bientôt la première dose de son essai clinique de phase 1 et compte fournir des mises à jour régulières sur ses progrès.
CERo Therapeutics Holdings (NASDAQ: CERO) hat erfolgreich die Einhaltung der Mindestanforderung an das Eigenkapital von Nasdaq in Höhe von 2,5 Millionen US-Dollar wiederhergestellt. Die Einhaltung wurde durch mehrere finanzielle Maßnahmen erreicht, darunter eine Privatplatzierung von Series D Vorzugsaktien, eine teilweise Inanspruchnahme der Eigenkapitalkreditlinie des Unternehmens sowie ein im Februar 2025 abgeschlossenes öffentliches Angebot.
Das Nasdaq Hearings Panel bestätigte die Einhaltung am 7. Mai 2025. CEO Chris Ehrlich betonte, dass sich das Unternehmen nun auf die Weiterentwicklung seines führenden Programms CER-1236, einer Immuntherapie gegen Krebs, konzentrieren kann. CERo plant, bald die erste Dosis seiner Phase-1-Studie zu verabreichen und regelmäßige Updates zum Fortschritt bereitzustellen.
- Successfully regained Nasdaq compliance, avoiding potential delisting
- Secured multiple funding sources through Series D Preferred Stock, Equity Line of Credit, and public offering
- Phase 1 clinical trial for CER-1236 cancer immunotherapy program to begin soon
- Recent financial struggles evidenced by the need to meet minimum equity requirements
- Multiple funding rounds suggest potential dilution for existing shareholders
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of
On May 7, 2025 the Nasdaq Hearings Panel (the “Panel”) notified the Company that following the execution of its private placement of Series D Preferred Stock on 4/21/2025, a partial drawdown from the Company’s Equity Line of Credit, and the closing of a public offering in February 2025, the Panel has determined that the Company now complies with the Equity Rule.
Chris Ehrlich, CERo Therapeutics CEO added, “We have worked diligently while communicating regularly with the team at Nasdaq in order to arrive at this outcome. Having achieved compliance, we are now poised to turn all of our efforts toward the progression of our lead program, CER-1236 and to fulfilling our goal of being a successful clinical stage biotechnology company developing immunotherapy for cancer. We anticipate the achievement of administering the first dose of our Phase 1 clinical trial in the near term, and to providing stakeholders with regular updates on our progress.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo and the implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
